Adopting a multi-proteomic approach, we evaluated the possible involvement of GARS1 in the regulation of phenotypic alterations that reduced in vivo tumorigenicity of A549 cells exposed to Fraisinib over time. For this purpose, we performed a differential proteomic analysis followed by the generatio...
Multi-omics reveals a new mechanism by which GARS1 drives bladder cancer progression through ASNS: purine metabolism reprogramming, mTORC1 activation, and intratumoral microbiota dysbiosis
